Marc Tessier-Lavigne Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Marc Tessier-Lavigne.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Marc Tessier-Lavigne. Marc Tessier-Lavigne is EVP, RESEARCH DRUG DISCOVERY in GENENTECH INC ($DNA) and Director in PFIZER INC ($PFE) and Director in REGENERON PHARMACEUTICALS INC ($REGN) and Director in AGIOS PHARMACEUTICALS INC ($AGIO) and Director in Juno Therapeutics, Inc. ($JUNO) and Director in Denali Therapeutics Inc. ($DNLI).
Latest Insider Trading Transactions of Marc Tessier-Lavigne
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AGIO, DNLI, DNA, JUNO, PFE, REGN
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 04 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 63.76 | 6,222 | 396,715 | 6,222 | |
Jun 04 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Grant | A | 0.00 | 2,074 | 0 | 2,544,370 | 2.5 M to 2.5 M (+0.08 %) |
May 24 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 60.03 | 8,806 | 528,580 | 2,542,296 | 2.6 M to 2.5 M (-0.35 %) |
May 24 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 60.13 | 37,957 | 2,282,468 | 2,551,102 | 2.6 M to 2.6 M (-1.47 %) |
Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 71.35 | 1,031 | 73,563 | 2,642,296 | 2.6 M to 2.6 M (-0.04 %) |
Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 69.59 | 3,482 | 242,309 | 2,643,327 | 2.6 M to 2.6 M (-0.13 %) |
Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 68.50 | 6,011 | 411,778 | 2,646,809 | 2.7 M to 2.6 M (-0.23 %) |
Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 67.57 | 14,945 | 1,009,834 | 2,652,820 | 2.7 M to 2.7 M (-0.56 %) |
Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 66.55 | 18,316 | 1,219,003 | 2,667,765 | 2.7 M to 2.7 M (-0.68 %) |
Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 65.63 | 37,445 | 2,457,665 | 2,686,081 | 2.7 M to 2.7 M (-1.37 %) |
Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 64.36 | 18,770 | 1,208,056 | 2,723,526 | 2.7 M to 2.7 M (-0.68 %) |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 482.68 | 3,613 | 1,743,923 | 3,613 | |
Jan 05 2021 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Grant | A | 0.00 | 248 | 0 | 2,078 | 1.8 K to 2.1 K (+13.55 %) |
Jun 18 2020 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 26.10 | 400,000 | 10,440,000 | 2,739,043 | 3.1 M to 2.7 M (-12.74 %) |
Jun 18 2020 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 26.10 | 400,000 | 10,440,000 | 2,739,043 | 3.1 M to 2.7 M (-12.74 %) |
Jun 05 2020 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 0.00 | 3,253 | 0 | 3,253 | |
Jun 05 2020 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 28.82 | 15,183 | 437,574 | 15,183 | |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | M | 177.82 | 15,000 | 2,667,300 | 0 | |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 566.01 | 100 | 56,601 | 1,830 | 1.9 K to 1.8 K (-5.18 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 565.35 | 900 | 508,815 | 1,930 | 2.8 K to 1.9 K (-31.80 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 564.45 | 6,600 | 3,725,370 | 2,830 | 9.4 K to 2.8 K (-69.99 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 563.45 | 6,375 | 3,591,994 | 9,430 | 15.8 K to 9.4 K (-40.34 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 562.65 | 1,025 | 576,716 | 15,805 | 16.8 K to 15.8 K (-6.09 %) |
May 08 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Buy | M | 177.82 | 15,000 | 2,667,300 | 16,830 | 1.8 K to 16.8 K (+819.67 %) |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 374.12 | 4,361 | 1,631,537 | 4,361 | |
Jan 06 2020 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Grant | A | 0.00 | 320 | 0 | 1,830 | 1.5 K to 1.8 K (+21.19 %) |
May 31 2019 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 19.50 | 27,245 | 531,278 | 27,245 | |
Jun 15 2018 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 18.92 | 27,830 | 526,544 | 27,830 | |
Dec 12 2017 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | C | 0.00 | 25,000 | 0 | 0 | |
Dec 12 2017 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Buy | C | 0.00 | 25,000 | 0 | 3,139,043 | 3.1 M to 3.1 M (+0.80 %) |
Dec 08 2017 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 18.00 | 47,165 | 848,970 | 47,165 | |
Jan 05 2017 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 376.69 | 7,830 | 2,949,483 | 7,830 | |
Jun 23 2016 | AGIO | AGIOS PHARMACEUTIC ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 47.33 | 8,500 | 402,305 | 48,875 | |
Jun 21 2016 | JUNO | Juno Therapeutics, ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 42.40 | 12,000 | 508,800 | 12,000 | |
Jan 06 2016 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 520.01 | 9,212 | 4,790,332 | 9,212 | |
Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | M | 57.11 | 5,000 | 285,550 | 5,000 | |
Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 595.44 | 500 | 297,720 | 1,187 | 1.7 K to 1.2 K (-29.64 %) |
Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 593.64 | 2,000 | 1,187,280 | 1,687 | 3.7 K to 1.7 K (-54.24 %) |
Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 590.17 | 1,000 | 590,170 | 3,687 | 4.7 K to 3.7 K (-21.34 %) |
Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 584.07 | 1,500 | 876,105 | 4,687 | 6.2 K to 4.7 K (-24.24 %) |
Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Buy | M | 57.11 | 5,000 | 285,550 | 6,187 | 1.2 K to 6.2 K (+421.23 %) |
Jun 25 2015 | AGIO | AGIOS PHARMACEUTIC ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 103.63 | 11,262 | 1,167,081 | 40,375 | |
Jun 16 2015 | JUNO | Juno Therapeutics, ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 60.00 | 12,000 | 720,000 | 12,000 | |
Apr 24 2015 | PFE | PFIZER INC | Tessier-Lavigne Marc | Director | Option Exercise | A | 0.00 | 4,596 | 0 | 29,100 | |
Feb 27 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | M | 50.91 | 3,000 | 152,730 | 9,279 | |
Feb 27 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 424.44 | 300 | 127,332 | 1,187 | 1.5 K to 1.2 K (-20.17 %) |
Feb 27 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 423.64 | 1,100 | 466,004 | 1,487 | 2.6 K to 1.5 K (-42.52 %) |
Feb 27 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 420.33 | 1,600 | 672,528 | 2,587 | 4.2 K to 2.6 K (-38.21 %) |
Feb 27 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Buy | M | 50.91 | 3,000 | 152,730 | 4,187 | 1.2 K to 4.2 K (+252.74 %) |
Mar 30 2009 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Option Exercise | D | 85.83 | 75,000 | 6,437,250 | 0 | |
Mar 30 2009 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Option Exercise | D | 79.55 | 57,000 | 4,534,350 | 0 | |
Mar 30 2009 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Option Exercise | D | 79.17 | 72,000 | 5,700,240 | 0 | |
Mar 30 2009 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Option Exercise | D | 73.47 | 55,000 | 4,040,850 | 0 | |
Mar 30 2009 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Option Exercise | D | 53.23 | 5,625 | 299,419 | 0 | |
Mar 30 2009 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Sell | D | 95.00 | 1,159 | 110,105 | 0 | 1.2 K to 0 (-100.00 %) |
Jul 18 2008 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Option Exercise | M | 53.23 | 18,750 | 998,063 | 5,625 | |
Jul 18 2008 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Sell | S | 79.90 | 18,750 | 1,498,125 | 1,159 | 19.9 K to 1.2 K (-94.18 %) |
Jul 18 2008 | DNA | GENENTECH INC | Tessier-Lavigne Marc | EVP, RESEARCH DRUG ... | Buy | M | 53.23 | 18,750 | 998,063 | 19,909 | 1.2 K to 19.9 K (+1,617.77 %) |
Page: 1